WHO vaccine-preventable diseases: monitoring system. 2019 global summary

Last updated 15-July-2019 (data as of 1-July-2019)
Next overall update Winter 2019
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 47'4501 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 54'3271 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2018  2017  2016  2015  2014  2000  1990  1980 
Total population 83'124  82'658  82'194  81'787  81'450  81'401  79'054  78'283 
Births 779  767  753  737  720  748  829  813 
Surviving infants 776  765  750  734  718  745  823  802 
Pop. less than 5 years 3'869  3'732  3'604  3'493  3'429  3'916  4'349  3'959 
Pop. less than 15 years 11'322  11'118  10'944  10'810  10'794  12'758  12'608  14'538 
Female 15-49 years 34'910  35'108  35'323  35'556  35'871  39'750  39'769  39'521 

Number of reported cases

(Click for retrospective incidence data for Germany)
Diphtheria
ChartChart
  26  11  14  19 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  543  929  326  2'464  443  28'745 
Mumps
ChartChart
  534  652  741  699  837 
Pertussis
ChartChart
  12'907  16'183  13'809  9'000  12'260  258 
Polio*
 
Rubella
ChartChart
  16  74  95  90  151 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  18  21 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Germany)
Vaccine year result method % card seen                                                
BCG         
DTP1          99  99  99  99  99 
DTP3          78  80 
IPV1          98  98  98  99  99 
HepB_BD         
HepB3          87  87  88  88  88  45 
Hib3          92  93  93  94  94  82 
JapEnc         
MCV1          97  97  97  97  97  92  50 
MCV2          93  93  93  93  93 
MenA         
PCV1          90  89  88 
PCV2         
PCV3          84  84  86  85  85 
Pol3          93  94  95  95  95  95  85 
Rota1          79  78  78 
RotaC          68  67 
RCV1          97  97  97  97  96 
TT2plus          80 
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid July 2020

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Germany)
DTP1
ChartChart
  98  98  98  98  98  96  93 
DTP3
ChartChart
  93  93  93  93  93  90  80 
HepB3
ChartChart
  87  87  87  87  87  84 
HepB_BD
ChartChart
 
Hib3
ChartChart
  92  92  92  92  92  94 
IPV1
  98  98  98  98 
MCV1
ChartChart
  97  97  97  97  97  92  75  25 
MCV2
ChartChart
  93  93  93  93  93 
PCV3
ChartChart
  84  84  84  84  84 
Pol3
ChartChart
  93  93  93  93  93  94  80  80 
RCV1
ChartChart
  97  97  97  97  97  92 
RotaC
ChartChart
  68  68  68  68  67 

Click to download WHO-UNICEF coverage estimates data for PAB time series.
Click to download WHO-UNICEF coverage estimates data for HPV time series.

Number of districts in the country 401  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2018 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaP 2, 3, 4, 11-14 months; Yes
DTaPHibHepBIPV 2, 3, 4, 11-14 months; Yes
DTaPHibIPV 2, 3, 4, 11-14 months; Yes
HepB_Pediatric 2, 4, 11-14 months; Yes
HPV 9-14 years (x2); Yes females and males
Influenza_Adult >=60 years; Yes and adults with chronic conditions, pregnant women, healthcare workers, residents living in long-term care facilities, Hajj or other travellers, other risk groups
Influenza_Pediatric Yes children with chronic conditions
MenC_conj 12-23 months; Yes
MMR 11-14, 15-23 months; Yes MMR and monovalent varicella immunization is preferable administered as two separate injections due to higher rates of febrile seizures following immunization with MMRV, MMRV is preferably administered as the second dose; and adults born after 1970
MMRV 15-23 months; Yes MMR and monovalent varicella immunization is preferable administered as two separate injections due to higher rates of febrile seizures following immunization with MMRV, MMRV is preferably administered as the second dose
Pneumo_conj 2, 4, 11-14 months; Yes
Pneumo_ps >=60 years; Yes
Rotavirus 6, 10, 14 weeks; Yes 3rd dose depending on vaccine presentation
Td >18 years; every 10 years
Tdap 5-6, >18 years; Yes
TdaPIPV 9-16 years; Yes
Varicella 11-14, 15-23 months; Yes MMR and monovalent varicella immunization is preferable administered as two separate injections due to higher rates of febrile seizures following immunization with MMRV, MMRV is preferably administered as the second dose
Zoster >=60 years; Yes (HZ/su) since Dec 2018

Immunizaton indicators

Indicator Expected answer 2018  2017  2016  2015  2014  2013  2012 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  No  No  No  No 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number 401  402  402  402  402  402  402 
Nº districts with DTP3 coverage >=80% number              
Nº districts with measles (MCV1) coverage >=95% number   298  308  268       
% of districts with MCV1 coverage >=95% From 0 to 100%   74  77  67       

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND NA  Yes  NA  Yes  No  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%           NA  NA 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2019 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  UN Inter-agency Group for Child Mortality Estimation (https://childmortality.org/data)  
 3  "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.